Advertisement

P387. PRAX-114, An Extrasynaptic-Preferring GABAA Receptor Positive Allosteric Modulator: A Phase 2 Trial Evaluating Multiple Dose Safety, Tolerability, and Preliminary Efficacy in Major Depressive Disorder

      PRAX-114 is an extrasynaptic-preferring GABAA receptor positive allosteric modulator in development for treatment of major depressive disorder (MDD). Extrasynaptic preference was hypothesized to explain preclinical findings demonstrating >20-fold separation between antidepressant- and sedative-like doses in rodents, and the lack of dose-limiting sedation in a Phase 1 trial assessing PRAX-114 safety and tolerability in healthy participants. Here we report results from an open-label Phase 2 trial assessing safety, tolerability and preliminary efficacy in MDD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect